Please assess the completion status of the following clinical trial:

Trial Title: CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a history of CD19+ lymphoid malignancies that are beyond first remission or primary refractory to treatment.~2. Age 18 to 75 years.~3. Zubrod performance 0-1 or Karnofsky greater than or equal to 80%.~4. Patient able to provide written informed consent.~5. Patient able to provide written informed consent for the long-term follow-up gene therapy study.~6. Eligibility at time of transplant conditioning regimen (criteria 6-13): Zubrod performance 0-1 or Karnofsky greater than or equal to 80%.~7. Left ventricular ejection fraction \>/= 40%. No uncontrolled arrhythmias or uncontrolled symptomatic cardiac disease.~8. No symptomatic pulmonary disease. FEV1, FVC and DLCO \>/= 50% of expected, corrected for hemoglobin.~9. Serum creatinine \</= 1.8mg/dL or creatinine clearance \>/= 40 cc/min.~10. Adequate hepatic function, as defined by SGPT \<3 X upper limit of normal; serum bilirubin and alkaline phosphatase \<2 X upper limit of normal, or considered not clinically significant.~11. If positive Hepatitis B and/or Hepatitis C serology, discuss with Principal Investigator or designee and consider liver biopsy.~12. No pleural/pericardial effusion or ascites estimated to be \>1L.~13. Not breast feeding or pregnant. Pregnancy determined by a positive beta HCG test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization.~14. Eligibility at time of T-cell infusion (criteria 14-15): No systemic corticosteroids within 3 days prior to T-cell infusion.~15. Not experiencing any new Grade \>2 (CTC version 4) adverse neurologic, pulmonary, cardiac, gastrointestinal, renal or hepatic (excluding albumin) event within 24 hours prior to T-cell infusion.~16. Eligibility criteria for administration of IL-2 after T-cell infusion: Absence of new adverse event of grade \>2 (CTC vs. 4) involving cardiopulmonary, hepatic (excluding albumin), gastrointestinal, neurologic, or renal toxicity probably or definitely attributed to infused T cells within one week of cells.~Exclusion Criteria:~1. Positive beta HCG in female of child-bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.~2. Patients with known allergy to bovine or murine products.~3. Positive serology for HIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CD19-specific T cell Infusion without IL-2 (Type: EXPERIMENTAL): Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 1 - low dose of T cells without IL-2.~Group 3 - higher dose of T cells without IL-2.
- CD19-specific T cell Infusion with IL-2 (Type: EXPERIMENTAL): Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 2 - higher dose of T cells with IL-2.~Group 4 - higher dose of T cells with IL-2.

Based on this trial design, predict the completion outcome and termination type (if applicable).